Aortic Valve Stenosis With Insufficiency

2

Review clinical trials related to Aortic Valve Stenosis With Insufficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study

This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.

Participants needed: 1,500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: Jun 3, 2024Locations: 1
Eligibility criteria

Age ≥ 18 years [+4]

History of prior valve surgery or percutaneous valve intervention (concerning a... [+2]

Status: Not yet recruiting

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

To collect information about the management of symptomatic severe Aortic Stenosis (AS) and Aortic Regurgitation (AR) using transcatheter aortic valve replacement (TAVI).

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: JenaValve Technology, Inc.Updated: Jan 11, 2023Locations: 3Duration: 5 Years
Eligibility criteria

Patients who have signed ICF and are indicated by their doctors to be treated wi... [+4]

Patients who have known hypersensitivity or contraindication to Nitinol (titaniu... [+7]